Prevalence of c-myc expression in breast lesions associated with microcalcifications detected by routine mammography.

Context And Objective: Genetic abnormalities in cell proliferation-regulating genes have been described in premalignant lesions. The aims here were to evaluate c-myc protein expression in non-palpable breast lesions associated with microcalcifications, detected by screening mammography, and to compare these results with histopathological, clinical and epidemiological variables.

Design And Setting: Analytical cross-sectional study, with retrospective data collection, in a university hospital in São Paulo.

Impact of breast MRI on surgical treatment, axillary approach, and systemic therapy for breast cancer.

The purpose of this study is to determine how often breast magnetic resonance imaging (MRI) brings additional information that influences management of patients with breast cancer concerning surgical treatment, axillary lymph node approach, and systemic therapy. From July 2004 to July 2005, 99 patients recently diagnosed with breast cancer in clinical stages 0, I, and II were prospectively evaluated about their therapeutic plans, at first based on usual protocol (physical examination, mammography and ultrasound) and next going through bilateral breast MR. Examinations were carried out at 1.

S100P calcium-binding protein expression is associated with high-risk proliferative lesions of the breast.

Benign breast diseases represent the vast majority of diagnosis in breast pathology. However, the limited capability in identifying lesions at high risk of breast cancer evolution is an increasing problem in clinical practice. In the present study, we tested the hypothesis that the overexpression of S100P calcium-binding protein, previously identified in the very early stages of breast carcinogenesis, could be used as a marker to differentiate lesions at high risk of malignant evolution.

Randomized clinical trial comparing conjugated equine estrogens and isoflavones in postmenopausal women: a pilot study.

Objective: The aim of this study was to evaluate the effects of isoflavone on the climacteric symptoms (Kupperman Menopausal index), vaginal pH, vaginal cytology (vaginal maturation index) and endometrium (evaluated by ultrasound and biopsy) in postmenopausal women.

Methods: It was a single-center, 6-month, randomized, double-blind, estrogen-controlled trial. Seventy-nine women were randomly assigned to one of the two treatment groups: isoflavone (n=40): 300 mg of the standardized soy extract with a medium dose of 120 mg isoflavones/day as glycoside and aglycone (60 mg twice a day), or estrogen (n=39): one capsule of 0.